iOS app Android app

Fda Biosimilars

Approved Pathway for Biosimilars Must Be Patient-Focused

Eva M. Clayton | Posted 08.25.2012 | Healthy Living
Eva M. Clayton

The U.S. pharmaceutical industry has worked hard to become an international leader in the production of biotech drugs. But as the nation introduces these medicines, we need to ensure that safety protocols are in place -- so that every patient has the opportunity to get healthy.

Are Unsafes Drugs An 'Acceptable Risk?' FDA Should Say 'No!'

John Horton | Posted 05.25.2011 | Home
John Horton

As a matter of common sense, the FDA's process for biosimilars shouldn't sacrifice patient safety.